Drug Type Small molecule drug |
Synonyms Albumin-bound docetaxel, Nab-docetaxel, ABI-008 + [4] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Phase 3 | - | 12 Aug 2024 | |
| Pancreatic adenocarcinoma | Phase 3 | China | 29 Jul 2024 | |
| Squamous non-small cell lung cancer | Phase 3 | - | 01 May 2024 | |
| Gastroesophageal junction adenocarcinoma | Phase 3 | China | 15 Mar 2024 | |
| stomach adenocarcinoma | Phase 3 | China | 15 Mar 2024 | |
| Stomach Cancer | Phase 3 | China | 27 Feb 2024 | |
| HER2 Positive Breast Cancer | Phase 3 | China | 23 Jul 2023 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | - | 15 Sep 2025 | |
| Advanced breast cancer | Phase 2 | China | 01 Aug 2025 | |
| Advanced gastric carcinoma | Phase 2 | China | 04 Jun 2025 |
Phase 2 | 128 | scpwfhadik(wzthacgnjy) = ijwfuciztw bdyznohepg (hgxmhmjgbv, 2.8 - 4.2) View more | Positive | 23 Jan 2025 | |||
scpwfhadik(wzthacgnjy) = xhkbvwcwwd bdyznohepg (hgxmhmjgbv, 1.8 - 3.0) View more | |||||||
NCT04931823 (ASCO2024) Manual | Phase 1 | 34 | rpmrfoqryd(wiohstapvm) = rlojpqtfye jypxzkzpmb (psgvqzbgoq ) View more | Positive | 24 May 2024 | ||
NCT05705635 (ASCO2024) Manual | Phase 2 | 125 | HB1801 (albumin-bound docetaxel) | tiyarkgcpg(okifjbencf) = bpthucgxbi noythjyurb (gvucszbuhx, 12.88 - 39.54) View more | Positive | 24 May 2024 | |
docetaxel (Taxotere) | tiyarkgcpg(okifjbencf) = umllqbrsjx noythjyurb (gvucszbuhx, 6.20 - 28.31) View more |





